The North America Recombinant Proteins Market would witness market growth of 10.3% CAGR during the forecast period (2022-2028).
Today, a range of recombinant proteins, such as those utilised in medical therapies, are produced using various bioprocessing processes. In the recombinant protein market, worldwide, for instance, vaccinations are produced using recombinant DNA technology to help prevent the spread of illnesses. It can also be utilized to make pharmaceuticals and other healthcare products. Utilizing recombinant protein has numerous advantages. One benefit is that recombinant protein products are more precise and reliable than those produced using conventional techniques.
In September 2020, GigaGen Inc. began mass manufacture of its first-in-class recombinant hyperimmune medication GIGA-2050 for the treatment of COVID-19 in association with Waisman Biomanufacturing and Goodwin Biotechnology Inc.
Due to rising research spending, a developed healthcare system, and a number of significant market players, North America is predicted to lead the recombinant protein market. Recombinant proteins are one of the tried-and-true treatments for the chronic diseases that are becoming more prevalent throughout the region, which is driving up demand for recombinant protein therapies. Effective therapies are required due to the rising incidence of cancer.
The US market dominated the North America Recombinant Proteins Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $708.8 million by 2028. The Canada market is poised to grow at a CAGR of 12.8% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 11.8% during (2022 - 2028).
Based on Product, the market is segmented into Growth Factors & Chemokines, Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors, Structural Proteins, Membrane Proteins, Kinase Proteins & Regulatory Proteins, Immune Response Proteins, and Others. Based on End User, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others. Based on Application, the market is segmented into Drug Discovery & Development, Academic Research Studies, Biopharmaceutical Production, Diagnostics, Biotechnology Research, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Recombinant Proteins Market is Predict to reach $2.6 Billion by 2028, at a CAGR of 10.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Thermo Fisher Scientific, Inc., Merck Group, Bio-Rad Laboratories, Inc., Abcam plc, Genscript Biotech Corporation, Miltenyi Biotec B.V. & Co. KG, Proteintech Group, Inc., BPS Bioscience, Inc., and RayBiotech Life, Inc.
By Product
By End User
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 